ORMP · ISSUER CIK 1176309
ORAMED PHARMACEUTICALS INC.
Between Aug 1, 2026 and Oct 29, 2026, 4 ORAMED PHARMACEUTICALS INC. insiders reported $0.00 of open-market purchases and $226K of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$226KInsider selling
−$226KNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202617:19 | Oct 1, 2026 | ORMP | Chief Financial Officer | S · Sell10b5-1 | $4.51 | −20,000 | 861,076 | -2% | −$90K | ||
| Oct 2, 202617:19 | Oct 1, 2026 | ORMP | COO & CBO | S · Sell10b5-1 | $4.51 | −30,000 | 1,328,130 | -2% | −$135K | ||
| Sep 25, 202616:31 | Sep 24, 2026 | ORMP | President and CEO, Director | A · Grant | — | +718,262 | 4,140,505 | +21% | — | ||
| Sep 25, 202616:31 | Sep 24, 2026 | ORMP | COO & CBO | A · Grant | — | +284,746 | 1,358,130 | +27% | — | ||
| Sep 25, 202616:30 | Sep 24, 2026 | ORMP | Chief Scientific Officer, Director | A · Grant | — | +417,416 | 1,550,554 | +37% | — | ||
| Sep 25, 202616:30 | Sep 24, 2026 | ORMP | Chief Financial Officer | A · Grant | — | +209,291 | 881,076 | +31% | — |